In many U.S. medical centers, K. pneumoniae isolates from patients frequently produce extended-spectrum ␤-lactamases (ES␤Ls) that confer resistance to penicillins, cephalosporins, and aztreonam. However, these isolates typically remained susceptible to carbapenems, which are considered the drugs of choice for treating infections due to ES␤L-producing bacteria.
In 1996, however, a carbapenem-resistant K. pneumoniae was recovered from a patient in North Carolina. This isolate produced a Class A ␤-lactamase, which hydrolyzes penicillins, cephalosporins, aztreonam, and carbapenems, and it shares about 45% identity with other Class A carbapenem-hydrolyzing enzymes (SME-1, Nmc-A, and IMI-1). Aptly named K. pneumoniae carbapenemase (KPC), this enzyme soon began appearing sporadically in K. pneumoniae isolates from hospitals in Maryland and New York City.
By the turn of this century, K. pneumoniae with KPC was emerging as a serious threat in medical centers throughout New York City. In 2001-2002, for example, an outbreak in an intensive care unit (ICU) at one Manhattan hospital occurred, and the strains were found to produce a variant of the originally described ␤-lactamase (KPC-3). By 2003 By -2004 , hospitalwide outbreaks were occurring at medical centers in nearby Brooklyn. According to a survey of four such hospitals in 2004, 24% of single-
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• Since an isolate of K. pneumoniae with the KPC carbapenemase was first identified from a patient in North Carolina in 1996, similar isolates have been recovered on four continents.
• The gene encoding this ␤-lactamase resides on a plasmid, making it readily available for transfer to other gram-negative pathogens.
• Clinical laboratories face difficulties in identifying carbapenemase-producer strains, particularly when using automatic systems.
• Aminoglycosides, tigecycline, and the polymyxins are among the few agents available for treating patients who are infected with carbapenemase-producer strains. 
KPC Spreads beyond Klebsiella spp.
Many early reports emphasized the presence of KPC within the genus Klebsiella. However, the gene encoding this ␤-lactamase resides on a transferable plasmid, making it readily available for other gram-negative genera. For instance, Escherichia coli isolates from New York, New Jersey, and Ohio have been found to carry this enzyme, as have isolates from Israel and China. In addition, the enzyme is being found in isolates, mainly from the northeastern United States, of Enterobacter spp., Serratia marcescens, and Salmonella enterica. KPC is also spreading to bacteria other than Enterobacteriaceae, including a P. aeruginosa isolate from South America.
What is the genetic setting for bla KPC ? In some cases, bla KPC resides within a similar transposable element found among different species of bacterial pathogens. Further, KPC is found on variably sized plasmids, often in the company of other genes that confer resistance to antimicrobial agents, either encoding other ␤-lactamases or aminoglycoside-modifying enzymes. Such plasmids are efficient antimicrobial resistance packages, conferring survival advantages to bacterial pathogens in hospital environments.
Challenges Controlling the Spread of KPC-Producing Bacteria
How do these pathogens continue to spread so freely when so many medical centers follow infection control protocols to curtail multidrugresistant gram-negative pathogens? The challenge is at least twofold. For one, clinical laboratories continue to experience difficulties in identifying KPC producers (based on carbapenem susceptibility). Second, laboratories have difficulty in identifying patients whose gastrointestinal tracts are asymptomatically colonized with such organisms.
Many from difficulty with inoculum preparation. Thus, MICs may drop below the breakpoint for susceptibility if the inoculum is lower than recommended. Klebsiella cultures can be notoriously mucoid and adherent, making it difficult to achieve appropriate inocula. Susceptibility testing using an in-house prepared microdilution panel, prepared according to Clinical and Laboratory Standards Institute directions, provides a more reliable approach.
When tested by broth microdilution using carefully adjusted inocula, only 0 -5% of isolates are susceptible to imipenem or meropenem.
However, testing via agar diffusion methods is inconsistent. In one study, disk diffusion and E-test techniques reliably predicted carbapenem resistance among KPC-producers. Other studies show these methods not to be so reliable. In particular, scattered inner colonies can make the zones of inhibition difficult to read (Fig. 1) . In general, susceptibility testing that uses imipenem or meropenem is not sensitive for identifying KPC-producing K. pneumoniae and other KPC-producing Enterobacteriaceae.
Options for Improving KPC Detection
There are at least two susceptibility testing-based options for improving how isolates with KPC are detected. One involves using ertapenem in automated systems. Ertapenem susceptibility rates of KPC-positive K. pneumoniae range from 0 -6%, compared to 26 -29% for imipenem and 16 -52% for meropenem. Ertapenem yields similarly low susceptibility rates when tested via broth microdilution and agar diffusion methods. Thus, using ertapenem as the class agent for carbapenems more reliably identifies KPC-producers. A second option entails targeting susceptible isolates with unusually elevated carbapenem MICs (in the 2-4 g/ml range).
However, these options have problems. Resistance to ertapenem, likely a result of porin deficiencies, can develop in Klebsiella, Enterobacter, or other species lacking carbapenemases. These isolates tend to be susceptible to imipenem and meropenem (albeit with unusually elevated MICs), and these antibiotics have the potential to remain effective therapeutic agents. Therefore, where carbapenemase-producing strains are not endemic, using ertapenem as the class agent (or lowering the breakpoint for susceptibility for imipenem or meropenem) may make isolates appear inappropriately resistant to all carbapenems. Because
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Susceptibility test of a KPC-producing K. pneumoniae using the Etest methodology. Note the presence of scattered colonies, making it difficult to read the defined endpoint. (Reprinted from Emerg. Infect. Dis. 12: 1209 -1213, 2006.) many of these isolates are concomitantly resistant to fluoroquinolones and aminoglycosides, reporting them to be resistant to imipenem or meropenem could lead clinicians to forego using these potentially effective agents in favor of other unproven or more toxic agents.
Certainly if a clinical laboratory begins to detect carbapenem-resistant Enterobactereaceae, or isolates with MICs of 2-4 g/ml, concern should be raised. Performing a modified Hodge test (Fig.  2) may assist in confirming a carbapenemase, but this test is not standardized. Clinical laboratories might add a precautionary note to the susceptibility report for imipenem or meropenem susceptible isolates suspected of harboring carbapenemases. These isolates should be referred to a local health department or research facility for additional testing. Further, the clinical team might be advised to consult with an infectious diseases specialist.
Difficulties Identifying KPC-Colonized Patients Furthers Spread
Another reason why KPC-harboring bacteria are spreading so rapidly lies with difficulties in identifying KPCcolonized patients. Reliance on clinical cultures is not an accurate means for identifying patients harboring certain nosocomial pathogens (e.g., vancomycin-resistant enterococci or ES␤L-carrying Enterobacteriaceae). Patients who test positive via clinical cultures often represent only a small fraction of a far larger colonized population who remain asymptomatic. It appears this is also the case for patients with KPC-producing K. pneumoniae. For example, according to one report, the gastrointestinal tracts of 36% of patients in an ICU were colonized with KPC-producing K. pneumoniae, but only 14% of these patients tested positive by clinical culture. Environmental surfaces were also contaminated with KPCproducing bacteria. Controlling the spread of KPC producers will be difficult until alternative, more reliable, perhaps PCR-based detection methods are widely available.
Treating Patients Infected with KPC-Producing Enterobacteriaceae
Options for treating patients who are infected with KPC-producing K. pneumoniae (and other Enterobacteriaceae) are limited. Although some isolates may be reported susceptible to cephamycins and cefepime, the MICs for these agents hover around their breakpoints. As with carbapenems, extreme caution should be used when considering these agents for therapy, even if laboratory results deem the bacteria to be susceptible.
Adding a ␤-lactamase inhibitor such as clavulanic acid, which is effective against most Class A enzymes, might be expected to restore ␤-lactam activity. However, ␤-lactam MICs do not typically fall below the breakpoint for suscepti-
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Modified Hodge test used for screening for carbapenemase-producing bacteria. Briefly, a susceptible isolate of E. coli is streaked across a Mueller-Hinton plate to create a lawn of confluent growth. An imipenem disk is placed in the center of the plate, and each test isolate suspected of having a carbapenemase is streaked from the imipenem disk. Growth of the susceptible E. coli near the imipenem disk is evidence of carbapenemase activity, as found in isolate A. bility when combined with an inhibitor, and time-kill experiments with a carbapenem and clavulanic acid do not suggest this to be an effective treatment regimen.
Therefore, therapy generally involves non-␤-lactam antibiotics. Most isolates are resistant to fluoroquinolones and trimethoprimsulfamoxazole. However, some isolates prove susceptible to amikacin or gentamicin. In such cases, the aminoglycoside should be considered for therapy, while weighing their wellknown toxicities. Some KPC-possessing K. pneumoniae isolates are susceptible to tetracycline, but again MICs fall at or near breakpoints for susceptibility.
Tigecycline, which is bacteriostatic, is a glycylcycline with expanded activity against many Enterobacteriaceae, including those with ES␤Ls and KPC. However, its low serum levels warrant caution when using this agent to treat bacteremic infections. Finally, KPC-producing K. pneumoniae usually remain susceptible to the polymyxins, which have concentration-dependent bacterial killing. However, the published record of experience in using these agents to treat patients infected with KPC-producing bacteria is limited, and resistance to the polymyxins has been documented. Combining a polymyxin with rifampin may augment antimicrobial activity in vitro; whether this combination translates into improved clinical outcomes is unknown.
